Saito A, et al. - Researchers examined the utility of recombinant human fibroblast growth factor (rhFGF)-2 in combination with deproteinized bovine bone mineral (DBBM) vs rhFGF-2 alone, in the treatment of intrabony periodontal defects. They randomly assigned sites to receive 0.3% rhFGF-2+DBBM (test) or rhFGF-2 alone (control) in patients with periodontitis who had received initial periodontal therapy and had intrabony defects of > 3 mm. At 6 months, the two treatments showed no marked difference in clinical attachment level gain or patient-reported outcome measure, despite an enhanced radiographic outcome with the combination therapy.